Global peptic ulcer drugs market 2017-2021
About Peptic Ulcer Drugs
A peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.
Technavio’s analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Peptic Ulcer Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global peptic ulcer drugs market: AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.
Other Prominent Vendors in the market are: GlaxoSmithKline and Pfizer.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Bismuth-based quadruple therapy. Bismuth-based quadruple therapy has emerged as an alternative therapy to address the demand for anti-resistant drugs for the treatment of peptic ulcer. The traditional treatment regimen for peptic ulcer involves the use of clarithromycin or levofloxacin-based triple therapy, which became resistant to H. pylori bacteria, thus leaving most individuals untreated. To offset the impact of antibiotic resistance, the modern therapeutic approach for the treatment of peptic ulcer is based on bismuth-based quadruple therapy, which involves the use of drugs, such as bismuth salt, tetracycline, and metronidazole, for which antibiotic resistance is rarely encountered.”
According to the report, one of the major drivers for this market is economics of treating ulcer. The under use of antibiotic therapy for the treatment of peptic ulcer associated with H. pylori infection not only leads to unnecessary loss of productivity but also causes enormous economic loss to the individual. As per a CDC report, approximately 10%-15% of peptic ulcer adults living in the US are in poor health condition and unable to perform routine activities.
Further, the report states that one of the major factors hindering the growth of this market is Adverse effect of PPIs. As per the US FDA, the use of PPIs for acid suppression in peptic ulcer patients is associated with an increased risk of CDAD. C. difficile is a bacterium, which causes diarrhea that does not improve over time. Its symptoms include watery stools, abdominal pain, fever, and may even lead to severe intestinal conditions. CDAD causes loss of vital nutrients from the body, and its treatment involves administration of fluids rich in nutrients and electrolyte in combination with antibiotics. The US FDA recommends CDAD diagnosis for patients with diarrhea that does not improve over time.
AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.GlaxoSmithKline and Pfizer.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook